Cardiovascular primary prevention: How high should we set the bar?

Vinay Prasad, Andrae Vandross

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Recent trials in cardiovascular medicine have contradicted current practice, and, accordingly, are medical reversals. Extended-release niacin and fenofibrate have failed to provide mortality benefit when added to statin therapy, though both drugs have been used for this purpose for years. Cardiovascular primary prevention is no small matter. Annual spending on statins exceeded $19 billion in 2005, ezetimibe cost over $5 billion in 2007, and fenofibrate costs passed $1 billion in 2009. Given the tremendous price of these medications, and recent trials that have undermined years of practice, we propose that the bar for cardiovascular primary prevention has been raised. Large studies must show improvements in overall mortality before novel agents are recommended and used. The implications of this proposal are considered.

Original languageEnglish (US)
Pages (from-to)656-659
Number of pages4
JournalArchives of Internal Medicine
Volume172
Issue number8
DOIs
StatePublished - Apr 23 2012
Externally publishedYes

Fingerprint

Fenofibrate
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
Costs and Cost Analysis
Mortality
Niacin
Medicine
Drug Therapy
Ezetimibe

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Cardiovascular primary prevention : How high should we set the bar? / Prasad, Vinay; Vandross, Andrae.

In: Archives of Internal Medicine, Vol. 172, No. 8, 23.04.2012, p. 656-659.

Research output: Contribution to journalArticle

@article{a254b8baaa1d40228e7581551d62b089,
title = "Cardiovascular primary prevention: How high should we set the bar?",
abstract = "Recent trials in cardiovascular medicine have contradicted current practice, and, accordingly, are medical reversals. Extended-release niacin and fenofibrate have failed to provide mortality benefit when added to statin therapy, though both drugs have been used for this purpose for years. Cardiovascular primary prevention is no small matter. Annual spending on statins exceeded $19 billion in 2005, ezetimibe cost over $5 billion in 2007, and fenofibrate costs passed $1 billion in 2009. Given the tremendous price of these medications, and recent trials that have undermined years of practice, we propose that the bar for cardiovascular primary prevention has been raised. Large studies must show improvements in overall mortality before novel agents are recommended and used. The implications of this proposal are considered.",
author = "Vinay Prasad and Andrae Vandross",
year = "2012",
month = "4",
day = "23",
doi = "10.1001/archinternmed.2012.812",
language = "English (US)",
volume = "172",
pages = "656--659",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Cardiovascular primary prevention

T2 - How high should we set the bar?

AU - Prasad, Vinay

AU - Vandross, Andrae

PY - 2012/4/23

Y1 - 2012/4/23

N2 - Recent trials in cardiovascular medicine have contradicted current practice, and, accordingly, are medical reversals. Extended-release niacin and fenofibrate have failed to provide mortality benefit when added to statin therapy, though both drugs have been used for this purpose for years. Cardiovascular primary prevention is no small matter. Annual spending on statins exceeded $19 billion in 2005, ezetimibe cost over $5 billion in 2007, and fenofibrate costs passed $1 billion in 2009. Given the tremendous price of these medications, and recent trials that have undermined years of practice, we propose that the bar for cardiovascular primary prevention has been raised. Large studies must show improvements in overall mortality before novel agents are recommended and used. The implications of this proposal are considered.

AB - Recent trials in cardiovascular medicine have contradicted current practice, and, accordingly, are medical reversals. Extended-release niacin and fenofibrate have failed to provide mortality benefit when added to statin therapy, though both drugs have been used for this purpose for years. Cardiovascular primary prevention is no small matter. Annual spending on statins exceeded $19 billion in 2005, ezetimibe cost over $5 billion in 2007, and fenofibrate costs passed $1 billion in 2009. Given the tremendous price of these medications, and recent trials that have undermined years of practice, we propose that the bar for cardiovascular primary prevention has been raised. Large studies must show improvements in overall mortality before novel agents are recommended and used. The implications of this proposal are considered.

UR - http://www.scopus.com/inward/record.url?scp=84860356514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860356514&partnerID=8YFLogxK

U2 - 10.1001/archinternmed.2012.812

DO - 10.1001/archinternmed.2012.812

M3 - Article

C2 - 22529231

AN - SCOPUS:84860356514

VL - 172

SP - 656

EP - 659

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 8

ER -